Orchard Therapeutics Company
Orchard Therapeutics is a biotechnology company that develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. The company is dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Investors
Headquarters:
London, England, United Kingdom
Industry:
Gene Therapy
Employee Number:
51-100
Estimated Revenue:
$1M to $10M
Investors Number:
24
Investment Stage:
N/A
Investor Type:
Company
Funding Status:
IPO
Number Of Exists:
Series C
Technology:
Others
Last Funding Type:
Series C
Founded Date:
2015
Total Funding:
$310.5M